TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Celecoxib on Bone Ingrowth

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male VA bilateral TKA patients 18 years or older with primary OA diagnosis~Exclusion Criteria:~* Patients with osteoporosis, hypersensitivity to Celebrex, allergy to tetracycline, Sulfonamides, patient with asthma, urticaria, or allergic-type reactions to aspirin or NSAIDs.~* Patients who have had CABG.~* Patients with a history of peptic ulcer disease, duodenal ulcers.~* Female patients and patients diagnosed with unstable hypertension or hypotensive, with serum creative levels above 1.8-2.0 or diagnosed with severe renal disease.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: t

Study Arms:
- Arm #1 (Type: EXPERIMENTAL): Celebrex treatment group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Botswana Tenofovir Oral HIV Prophylaxis Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* citizen of Botswana 18-29 years old~* sexually active~* HIV uninfected~* Hepatitis B and C uninfected~* Calculated creatinine clearance \>= 60 mL/min~* hemoglobin \>= 8 gm/dL~* ALT and AST \<= 2x ULN~* total bilirubin \<= 1.5 mg/dL~* total serum amylase \<= 1.5x ULN~* Serum phosphorus \>= 2.2 mg/dL~* willing to use effective contraception~* living within 1 hours travel of study clinic~* pass comprehension test~* willing and able to give informed consent~Exclusion Criteria:~* history of significant renal or bone disease~* any chronic illness requiring ongoing prescription medication~* pregnant or breastfeeding~* planning to move away from site in the next year~* participating in another HIV prevention or vaccine safety trial~* any other clinical condition or prior therapy that, in the opinion of the study physician, would make the volunteer unsuitable for the study or unable to comply with the dosing requirements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 29 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dose-escalation Study of Quarfloxin in Patients With Advanced Solid Tumors or Lymphomas

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with histologically confirmed solid tumors or lymphomas.~* Tumor progression after receiving standard/approved chemotherapy or where there is no approved therapy.~* One or more tumors measurable on radiograph or CT scan, or evaluable disease (e.g., malignant ascites).~* Karnofsky performance status of greater than or equal to 70.~* Life expectancy of at least 3 months.~* Age at least 18 years.~* Patients must have central IV access, or agree to the insertion of a central IV line.~* Normal oxygen saturation by pulse oximetry on room air~* A negative pregnancy test (if female).~* Acceptable liver function as evaluated by laboratory results~* Acceptable renal function as evaluated by laboratory results~* Acceptable hematologic status as evaluated by laboratory results~* No clinically significant urinalysis abnormalities~* Acceptable coagulation status as evaluated by laboratory results~* Fertile men and women must use effective contraceptive methods during the study.~Exclusion Criteria:~* Seizure disorders requiring anticonvulsant therapy.~* Known brain metastases (unless previously treated and well controlled for a period of greater than or equal to 3 months).~* Severe chronic obstructive pulmonary disease with hypoxemia, or an uncorrectable pulmonary compromise.~* Major surgery, other than diagnostic surgery, within 4 weeks prior to the first dose of test drug.~* Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy.~* Pregnant or nursing women.~* Treatment with radiation therapy, surgery, chemotherapy, or investigational therapy within one month prior to study entry (6 weeks for nitrosoureas or Mitomycin C).~* Unwillingness or inability to comply with procedures required in this protocol.~* Known infection with HIV, hepatitis B, or hepatitis C.~* Clinically significant bleeding event within the last 3 months, unrelated to trauma, or underlying condition that would be expected to result in a bleeding diathesis.~* Patients who are currently receiving any other investigational agent.~* Patients who have exhibited allergic reactions to a similar structural compound (e.g., fluoroquinolones, biological agent or formulation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Quarfloxin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Metformin Plus Paclitaxel for Metastatic or Recurrent Head and Neck Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older~* Biopsy-proven head and neck squamous cell carcinoma~* Ineligibility for curative intent therapy, e.g., surgery or radiation therapy~* recurrent or stage IV disease~* previous failure to platinum-based chemotherapy~* measurable disease according to RECIST v1.1~* PS ECOG 0-2~Exclusion Criteria:~* known hypersensitivity to metformin or paclitaxel~* SNC metastasis~* Acute or chronic infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paclitaxel, placebo (Type: ACTIVE_COMPARATOR): Paclitaxel 175mg/m² q21d until disease progression, unacceptable toxicity or consent withdrawal
- Paclitaxel plus metformin (Type: EXPERIMENTAL): Paclitaxel 175mg/m² q21d + metformin up to 2500mg/d until disease progression, prohibitive toxicity or consent withdrawal

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Using Long Acting Antihistamine to Treat Opioid Induced Itching

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children age 6-18yrs on opioids who develop pruritus and are willing to participate in the study~Exclusion Criteria:~* Children with history of chronic urticaria~* Children with other chronic pruritic condition like eczema, contact dermatitis, psoriasis~* Children with known hypersensitivity to cetirizine/zyrtec~* Children on H1 antihistamine like diphenhydramine, hydroxyzine, cetirizine, loratadine, fexofenadine, chlorpheniramine within the last 7days prior to randomization~* Children who have received Ondansetron within 24hrs prior to randomization~* Children who are on Tricyclic antidepressants~* Children who are unwilling or unable to swallow the capsule.~* Children with chronic liver or kidney disease

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Cetirizine (Type: ACTIVE_COMPARATOR): zyrtec 10mg, oral, one time
- Sugar pill (Type: PLACEBO_COMPARATOR): Placebo, one pill, one time

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2a Study to Evaluate the Safety and Efficacy of Cannabidiol Only as Maintenance Therapy and Steroid Sparing in Patients With Stable Autoimmune Hepatitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with histologically confirmed chronic hepatitis~2. Age ≥18 years~3. Subject able to provide written informed consent~4. Stable disease for 24 months~5. Currently being administered prednisone (with or without azathioprine) therapy at the lower stable dose to maintain remission or Budesonide (with or without azathioprine) therapy at the lower stable dose to maintain remission or azathioprine alone.~6. ALT ≤ 30 U/L in men and ≤19 U/L in women~7. IgG \< 1450 mg/dL~8. Non-pregnant women (via negative pregnancy test) and women with no intention to become pregnant during the term of the trial or three months after cessation of CBD treatment~Exclusion Criteria:~1. Viral Hepatitis (HAV, HBV, HCV)~2. HIV~3. Serious psychiatric or psychological disorders~4. Active consumption of illicit drugs including cannabis or derivatives (at least 1 month before study start)~5. Overlap disease with Primary Biliary Cholangitis or Primary Sclerosing Cholangitis~6. IgG4 related Autoimmune Hepatitis~7. Transplant patients~8. Patients with significant cardiac, respiratory or active malignance disease comorbidities.~9. Renal comorbidity: eGFR \< 30 mL/min/1.73 m2 (note: CKD Grade 4 is defined as eGFR 15-29 mL/min/1.73 m2)~10. Cirrhosis~11. Patients treated with corticoids for other indication except Autoimmune Hepatitis~12. Patient that are taking immunomodulatory medications for other indication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sintetic Cannabidiol (Type: EXPERIMENTAL): Synthetic Cannabidiol, dissolved in pharmaceutical grade olive oil at a concentration of 5% will be administered orally twice a day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Pentoxifylline for Hepatopulmonary Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient undergoing liver transplantation evaluation for cirrhosis~* HPS (positive contrast echocardiography, hypoxemia, no other cause)~* PaO2 \< 65mmHg~* ability and willingness to give informed consent~Exclusion Criteria:~* Patients under the age of 19~* active bacterial infections~* known malignancy~* intrinsic cardiopulmonary disease~* known intolerance to pentoxifylline

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- single (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess Disability in Anemic Elderly Patients With Kidney Disease Receiving PROCRIT (Epoetin Alfa)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients having chronic anemia and chronic renal failure~* have lessened physical function~* be community dwelling (defined as not admitted to an assisted nursing facility, nursing home or hospital at the time of enrollment. An assisted nursing facility is considered any living situation where daily care is being provided by recognized health care professionals from that facility.)~Exclusion Criteria:~* History of bacterial infection requiring hospitalization and intravenous antibiotics or transfusion within 1 month prior to enrollment~* anemia due to iron, folate, or vitamin B12 deficiency~* gastrointestinal bleeding~* anticipated to begin dialysis within 4 months following enrollment into the study~* History of thrombotic disease within the past 3 months, or on anticoagulation therapy at enrollment.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Use of Diluted Povidone Iodine Irrigation in Spine Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age of 18-75~* Undergoing posterior surgical spinal procedure for degenerative spine disease, extra-dural tumors, trauma, or spinal deformity~* No obvious potential infective focus~* Patient willing to enroll~Exclusion Criteria:~* Age \<18 or \>75~* Identified infective focus in the body, including furuncles,or acne at surgical incision site~* Patient with discitis or spinal osteomyelitis~* Dural tear~* Potential use of Bone Morphogenic Protein (BMP)~* Iodine hypersensitivity~* Out of province patients due to difficulty in arranging follow up visits~* Minimal invasive spine surgical procedure (MISS) due to difficulty of having diluted Betadine solution contact soft tissue with the use if MISS retractors~* Pregnancy~* Inability to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Diluted Povidone Iodine Solution (Type: ACTIVE_COMPARATOR): None
- Normal Saline Wash (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Motor Imagery on Motor Learning and Motor Retention in Octogenarian.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Being part of the Proof cohort~* Signed written consent form~* Affiliated to social security~Exclusion Criteria:~* Pathology or chirurgical intervention causing locomotor disorder~* Neurological or psychic pathology~* Use psychotropic drugs~* Mini-Mental State Examination (MMSE) \< 20

- Gender: ALL
- Minimum Age: 80 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental group (Type: EXPERIMENTAL): Patient aged over 80 years old will be included. They will have motor imagery training of manual task and motor imagery training of motor task.
- Control group (Type: ACTIVE_COMPARATOR): Patient aged over 80 years old will be included. They will have emotionally neutral film as training of manual task and emotionally neutral film as training of motor task.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Transversus Abdominis Plane Block After Robot-assisted Laparocopic Hysterectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-80~* BMI 17-40~* Written consent~* Can cooperate~Exclusion Criteria:~* Drug and alcohol abuse~* Consumption of opioids~* Drug allergy~* Infection at insertion point of needle

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- TAP block (Type: EXPERIMENTAL): TAP block with ropivacaine
- Placebo TAP block (Type: PLACEBO_COMPARATOR): Sham block with saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with CML-CP treated for at least two years by Imatinib Mesylate 400 mg / d,~2. Patients in complete cytogenetic response for at least 1 year~3. Patients with residual disease detectable by quantitative RT-PCR (RQ-PCR)~4. ECOG ≤ 2,~5. Age ≥ 18 years~6. Signed informed consent,~7. Membership of a social security system~Exclusion Criteria:~1. Patients with CML-CP Philadelphia chromosome negative diagnosis.~2. Patients previously treated with Imatinib Mesylate at doses above 400 mg / day~3. Patient with non-hematologic toxicity of grade III or IV in Imatinib Mesylate 400mg / d~4. Patient with a medical condition endocrine, psychiatric, neurological, renal, hepatic or cardiac progressive uncontrolled by medical treatment~5. Pregnant or breastfeeding women, women of childbearing potential not using a contraceptive method effective~6. Known HIV positive~7. Patients previously treated with another tyrosine kinase inhibitor~8. Patient participating in another interventional clinical trial~9. History of non-compliance to Imatinib Mesylate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Imatinib 600 (Randomized trial) (Type: EXPERIMENTAL): Randomized Cohort: Adapted strategy of dosage of Imatinib Mesylate : 600mg/d po
- Imatinib 400 (Randomized trial) (Type: ACTIVE_COMPARATOR): Randomized Cohort: Standard strategy of dosage of Imatinib Mesylate : 400mg/d po
- Imatinib400 (Cohort) (Type: OTHER): Parallel Cohort: Standard strategy of dosage of Imatinib Mesylate : 400mg/d po

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Stool Sample Collection Protocol for Development of Screening Test for Colorectal Cancer and Other Digestive Tract Cancers

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject is male or female, 40-90 years of age, inclusive.~* Subject has a diagnosis of CRC, at any stage, confirmed with a tissue biopsy or colorectal polyp/adenoma/mass that is equal or larger than 1 cm in pre-enrollment colonoscopy with residual lesion in the colon of sufficient size to require additional surgical excision or complex colonoscopic polypectomy.~* Subject understands the study procedures and is able to provided informed consent to participate in the study and authorization for release of relevant protected health information to the study Investigator.~Exclusion Criteria:~* Subject has actively bleeding hemorrhoids (blood on toilet paper or bright red blood clots in the toilet bowel during bowel movement).~* Individual has a condition the Investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results or put the person at undue risk.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Colorectal cancer patients (Type: None): Subjects will be men and women, 40-90 years of age, inclusive, each with a colonoscopic biopsy-based diagnosis of colorectal cancer (CRC) and/or a pre-malignant colorectal lesion with large enough residual lesion to require subsequent surgical excision or complex colonoscopic polypectomy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: The Intracept Global Registry ( TIGR ) - Pilot Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~All patients scheduled for the Intracept procedure and whose treating physician is referring to the registry~Exclusion Criteria:~* No exclusion criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues